441 related articles for article (PubMed ID: 24495944)
1. Amplatzer PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta-analysis of randomised trials.
Pandit A; Aryal MR; Pandit AA; Jalota L; Kantharajpur S; Hakim FA; Lee HR
Heart Lung Circ; 2014 Apr; 23(4):303-8. PubMed ID: 24495944
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials.
Kwong JS; Lam YY; Yu CM
Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879
[TBL] [Abstract][Full Text] [Related]
3. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
4. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale.
Hornung M; Bertog SC; Franke J; Id D; Taaffe M; Wunderlich N; Vaskelyte L; Hofmann I; Sievert H
Eur Heart J; 2013 Nov; 34(43):3362-9. PubMed ID: 23842846
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.
Stortecky S; da Costa BR; Mattle HP; Carroll J; Hornung M; Sievert H; Trelle S; Windecker S; Meier B; Jüni P
Eur Heart J; 2015 Jan; 36(2):120-8. PubMed ID: 25112661
[TBL] [Abstract][Full Text] [Related]
7. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials.
Wang TKM; Wang MTM; Ruygrok P
Heart Lung Circ; 2019 Apr; 28(4):623-631. PubMed ID: 29602754
[TBL] [Abstract][Full Text] [Related]
8. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
9. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
[TBL] [Abstract][Full Text] [Related]
10. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
[TBL] [Abstract][Full Text] [Related]
11. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
[TBL] [Abstract][Full Text] [Related]
12. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
[TBL] [Abstract][Full Text] [Related]
13. Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta-analysis of randomised trials.
Nagaraja V; Raval J; Eslick GD; Burgess D; Denniss AR
Heart Lung Circ; 2013 Nov; 22(11):903-9. PubMed ID: 24035325
[TBL] [Abstract][Full Text] [Related]
14. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.
Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A
Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of percutaneous closure versus medical therapy for cryptogenic stroke in patients with a patent foramen ovale.
Pickett CA; Villines TC; Ferguson MA; Hulten EA
Am J Cardiol; 2014 Nov; 114(10):1584-9. PubMed ID: 25248812
[TBL] [Abstract][Full Text] [Related]
16. Ten years of experience with closure of persistent foramen ovale: patient characteristics and outcomes.
Lehmann R; Fichtlscherer S; Baldauf H; Schächinger V; Auch-Schwelck W; Zeiher AM; Teupe C
J Cardiol; 2014 Aug; 64(2):113-6. PubMed ID: 24480741
[TBL] [Abstract][Full Text] [Related]
17. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies.
Capodanno D; Milazzo G; Vitale L; Di Stefano D; Di Salvo M; Grasso C; Tamburino C
EuroIntervention; 2014 Mar; 9(11):1342-9. PubMed ID: 24240356
[TBL] [Abstract][Full Text] [Related]
18. A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke.
Kasner SE; Sondergaard L; Nakum M; Gomez Montero M; Hashim M; Landaas EJ
J Med Econ; 2024; 27(1):337-343. PubMed ID: 38373018
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events.
Pineda AM; Nascimento FO; Yang SC; Kirtane AJ; Sommer RJ; Beohar N
Catheter Cardiovasc Interv; 2013 Nov; 82(6):968-75. PubMed ID: 23832613
[TBL] [Abstract][Full Text] [Related]
20. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
